- Global Pharma News & Resources

Primary Immunodeficiency Diseases Epiomic Epidemiology Markets, 2018-2028 - Focus on 23 Key Countries

Primary Immunodeficiency Diseases Epiomic Epidemiology Markets, 2018-2028 - Focus on 23 Key Countries

PR Newswire

DUBLIN, Sept. 19, 2018

DUBLIN, Sept. 19, 2018 /PRNewswire/ --

The "Epiomic Epidemiology Series: Primary Immunodeficiency Diseases Forecast In 23 Major Markets 2018-2028" report has been added to's offering.

Primary immunodeficiency diseases (PID) are a group of inherited genetic disorders of the genes governing the immune system. PIDs are a group of more than 200 rare, chronic disorders in which part of the body's immune system is missing or functions improperly. Some types of PID affect a single part of the immune system while others may affect one or more components of the system. The result is a compensatory, often exaggerated and chronic inflammatory response by less effective alternative immune pathways, which damage not only infected cells but also surrounding tissue.

This report provides the current prevalent population for PID across 23 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Sweden, Austria, Switzerland, Greece, Czech Republic, Hungary, Turkey, Japan, China, India, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the publisher's analysis team, PID patients grouped by disease classification have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for PID include:

  • Severe Congenital Immunodeficiency (SCID)
  • Recurrent or persistent infections
  • Allergic manifestations
  • Respiratory diseases
  • Organ problems
  • Developmental delay

Reasons to buy

  • Ability to quantify patient populations in global PID market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the prevalence of the subdivided types of PID and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Identification of PID patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of PID patients.

Key Topics Covered:

  1. Introduction
  2. Cause Of The Disease
  3. Risk Factors & Prevention
  4. Diagnosis Of The Disease
  5. Variation By Geography/Ethnicity
  6. Disease Prognosis & Clinical Course
  7. Key Comorbid Conditions / Features Associated With The Disease
  8. Methodology For Quantification Of Patient Numbers
  9. Top-Line Prevalence For Primary Immunodeficiency Diseases
  10. Features Of Primary Immunodeficiency Diseases Patients
  11. Abbreviations Used In The Report
  12. Other Publisher Services & Solutions
  13. Reports & Publications
  14. Online Epidemiology Databases
  15. Online Pharmaceutical Pricing Database
  16. References
  17. Appendix

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets

Editor Details

Last Updated: 19-Sep-2018